Biopharmaceutical contract development and manufacturing organization (CDMO) Scorpion Biological Services (Scorpion) announced a planned development partnership with a private developer, the State of Kansas,...
Pharming Group N.V. announces that it has received a positive decision from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Paediatric...
Protagonist Therapeutics announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).
Also Read: Glass Lewis Proxy...
